Mind Medicine (MindMed) Inc
MNMD12.100USD
-0.190-1.55%
Cierre 11/03, 16:00（ET）Cotizaciones retrasadas 15 min
917.22MCap. mercado
PérdidaP/E TTM
Más Datos de Mind Medicine (MindMed) Inc Compañía
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Información de Mind Medicine (MindMed) Inc
Símbolo de cotizaciónMNMD
Nombre de la empresaMind Medicine (MindMed) Inc
Fecha de salida a bolsaMay 04, 2015
Director ejecutivoMr. Robert (Rob) Barrow
Número de empleados74
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 04
DirecciónOne World Trade Center
CiudadNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10007
Teléfono12122206633
Sitio Webhttps://ir.mindmed.co/
Símbolo de cotizaciónMNMD
Fecha de salida a bolsaMay 04, 2015
Director ejecutivoMr. Robert (Rob) Barrow
Ejecutivos de Mind Medicine (MindMed) Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
224.25K
-10.32%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.35K
-26.46%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Daniel R. Karlin, M.D.
Dr. Daniel R. Karlin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Matthew T. Wiley
Mr. Matthew T. Wiley
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Chris Brinzey
Mr. Chris Brinzey
IR Contact Officer
IR Contact Officer
--
--
Mr. Andreas R. Krebs
Mr. Andreas R. Krebs
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
224.25K
-10.32%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.35K
-26.46%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 15 de ago
Actualizado: vie., 15 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
5.38%
Commodore Capital LP
5.16%
Blackstone Alternative Asset Management, L.P.
3.70%
Marshall Wace LLP
3.53%
Driehaus Capital Management, LLC
3.19%
Otro
79.04%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
5.38%
Commodore Capital LP
5.16%
Blackstone Alternative Asset Management, L.P.
3.70%
Marshall Wace LLP
3.53%
Driehaus Capital Management, LLC
3.19%
Otro
79.04%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
22.81%
Hedge Fund
16.77%
Investment Advisor
13.84%
Research Firm
1.64%
Individual Investor
1.03%
Bank and Trust
0.36%
Pension Fund
0.19%
Venture Capital
0.17%
Insurance Company
0.04%
Otro
43.15%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
383
42.48M
55.83%
-5.92M
2025Q2
380
42.59M
55.97%
-6.05M
2025Q1
383
42.99M
56.91%
-5.37M
2024Q4
358
42.80M
58.58%
-14.39M
2024Q3
346
50.91M
62.84%
+1.65M
2024Q2
371
44.11M
63.15%
+4.97M
2024Q1
368
37.27M
54.54%
+28.87M
2023Q4
362
7.25M
18.10%
-366.43K
2023Q3
378
6.32M
16.16%
-494.13K
2023Q2
386
6.41M
16.75%
-688.87K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
5.22M
6.86%
+17.02K
+0.33%
Jun 30, 2025
Commodore Capital LP
5.00M
6.57%
+475.00K
+10.50%
Jun 30, 2025
Blackstone Alternative Asset Management, L.P.
3.59M
4.71%
--
--
Jun 30, 2025
Marshall Wace LLP
3.42M
4.5%
+828.07K
+31.93%
Jun 30, 2025
Driehaus Capital Management, LLC
3.09M
4.06%
-258.75K
-7.72%
Jun 30, 2025
Deep Track Capital LP
2.50M
3.29%
--
--
Jun 30, 2025
Octagon Capital Advisors LP
2.13M
2.8%
-888.00K
-29.42%
Jun 30, 2025
State Street Investment Management (US)
1.81M
2.37%
-36.32K
-1.97%
Jun 30, 2025
The Vanguard Group, Inc.
1.80M
2.37%
+47.45K
+2.70%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.73M
2.28%
+66.66K
+4.00%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
AdvisorShares Psychedelics ETF
10.44%
SPDR S&P Pharmaceuticals ETF
1.66%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
1.17%
iShares U.S. Pharmaceuticals ETF
0.33%
iShares Micro-Cap ETF
0.19%
ProShares Ultra Nasdaq Biotechnology
0.09%
Invesco Nasdaq Biotechnology ETF
0.09%
Vanguard US Momentum Factor ETF
0.07%
Nuveen ESG Small-Cap ETF
0.06%
Ver más
AdvisorShares Psychedelics ETF
Proporción10.44%
SPDR S&P Pharmaceuticals ETF
Proporción1.66%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.25%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.17%
iShares U.S. Pharmaceuticals ETF
Proporción0.33%
iShares Micro-Cap ETF
Proporción0.19%
ProShares Ultra Nasdaq Biotechnology
Proporción0.09%
Invesco Nasdaq Biotechnology ETF
Proporción0.09%
Vanguard US Momentum Factor ETF
Proporción0.07%
Nuveen ESG Small-Cap ETF
Proporción0.06%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Fecha
Tipo
Relación
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
